

Trovagene, Antonius Schuh and Stephen Zaniboni Resolve Employment Dispute

Jul 28, 2017

SAN DIEGO, July 28, 2017 /[PRNewswire](#)/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced that Trovagene, and Antonius Schuh and Stephen Zaniboni, the company's former Chief Executive Officer and former Chief Financial Officer, have resolved their respective legal claims against each other surrounding Trovagene's termination of Dr. Schuh and Mr. Zaniboni in March 2016. The parties stated that the time had come to focus on their respective endeavors without distraction and expense of further litigation.

Trovagene further stated that, after completing its investigation, it has come to the conclusion that Dr. Schuh and Mr. Zaniboni believed they acted at all times in a manner consistent with their duties as Trovagene officers. Trovagene expressed gratitude for their four years of service and wished them well in their future professional endeavors. Dr. Schuh and Mr. Zaniboni, after completing their investigation, stated they have come to the conclusion that Trovagene's Board of Directors believed it acted at all times in the best interest of the company's shareholders. Dr. Schuh and Mr. Zaniboni wished Trovagene well in its future endeavors.



About Trovagene, Inc.

Trovagene is a precision medicine biotechnology company developing oncology therapeutics for improved cancer care by leveraging its proprietary Precision Cancer Monitoring® (PCM) technology in tumor genomics. Trovagene has broad intellectual property and proprietary technology to measure circulating tumor DNA (ctDNA) in urine and blood to identify and quantify clinically actionable markers for predicting response to cancer therapies. Trovagene offers its PCM technology at its CLIA/CAP – accredited laboratory and plans to continue to vertically integrate its PCM technology with precision cancer therapeutics. For more information, please visit <https://www.trovagene.com>.

Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Trovagene's expectations, strategy, plans or intentions. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, our need for additional financing; our ability to continue as a going concern; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or

discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; uncertainties of government or third party payer reimbursement; dependence on key personnel; limited experience in marketing and sales; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; our ability to develop tests, kits and systems and the success of those products; regulatory, financial and business risks related to our international expansion and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that any of our technology or products will be utilized or prove to be commercially successful, or that Trovogene's strategy to design its liquid biopsy tests to report on clinically actionable cancer genes will ultimately be successful or result in better reimbursement outcomes. Additionally, there are no guarantees that future clinical trials will be completed or successful or that any precision medicine therapeutics will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Trovogene's Form 10-K for the year ended December 31, 2016, and other periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Trovogene does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.

Trovogene Contact:

Vicki Kelemen

VP, Corporate Communications

858-952-7652

vkelemen@trovogene.com

SOURCE Trovogene, Inc.

<http://trovogene.investorroom.com/2017-07-28-Trovogene-Antonius-Schuh-and-Stephen-Zaniboni-Resolve-Employment-Dispute>

<http://trovogene.investorroom.com/2017-07-28-Trovogene-Antonius-Schuh-and-Stephen-Zaniboni-Resolve-Employment-Dispute>